Better Artificial Intelligence (AI) Stock: Marvell Technology vs. Broadcom

Broadcom is projected to grow AI revenue to $16 billion in the current quarter and management expects AI revenue to exceed $100 billion in fiscal 2027, implying a quarterly run rate above $12 billion. Analysts expect Broadcom EPS to rise 71% this fiscal year and 62% next year, outpacing Marvell's 42% and 52% growth, respectively. The article argues Broadcom's weaker 13% year-to-date stock performance versus Marvell's nearly tripling leaves it with a cheaper valuation and better upside potential.

Analysis

AVGO looks like the cleaner second-order beneficiary of the AI capex cycle because its growth is increasingly becoming a function of concentration, not just end-market demand. When a handful of hyperscalers and foundation-model builders are in an arms race, the supplier with the deepest design-in footprint tends to compound faster than the one winning incremental share; that favors AVGO's leverage to program wins, software attach, and longer replacement cycles. MRVL can still participate, but its smaller scale and higher sentiment dependency make it more vulnerable to any pause in ordering or a single program delay.

The market’s current setup creates a subtle asymmetry: MRVL is priced like a momentum beneficiary, while AVGO is priced like a mature compounder still waiting for re-rating. That is usually where the better risk/reward lives if guidance keeps inflecting, because AVGO has more room for multiple expansion if investors start capitalizing its AI earnings stream as a structurally higher base rather than a cyclical spike. The second-order winner could be the broader AI infrastructure basket, because stronger AVGO guidance validates downstream spending plans for networking, optics, power, and rack-level suppliers.

The main risk is not demand; it is digestion. If hyperscalers pull forward too much spend into one or two quarters, the next few prints can look lumpy even if the multiyear trend remains intact, and that is where high-multiple names like MRVL can de-rate fastest. A more meaningful reversal would come from a capex optimization regime shift at the largest customers, where they prioritize utilization and ROI over raw buildout; that would hit MRVL first, then AVGO with a lag of several quarters.

Consensus may be underestimating how much AVGO's AI story can compound through fiscal 2027 if the company keeps converting custom silicon wins into follow-on networking and software revenue. The market is also likely overstating the permanence of MRVL's relative outperformance; a strong stock can stay strong, but once expectations embed trillion-dollar outcomes, the burden of proof rises sharply and volatility expands. In our view, the better trade is not chasing the relative winner, but positioning for AVGO to catch up as earnings revisions broaden and the market stops paying up for purely narrative-driven momentum.

Key Decisions for Investors

• Long AVGO on a 3-6 month horizon; use any post-earnings consolidation or 5-8% pullback as entry. Upside comes from earnings revision momentum and multiple re-rating; downside is limited unless AI capex guidance rolls over.
• Short MRVL vs long AVGO as a pair trade. Target a 2-3 quarter window where expectations normalization hurts the higher-beta name while AVGO benefits from broader customer diversification and stronger revision durability.
• Buy AVGO call spreads 4-9 months out to express upside with defined risk. This is preferable to outright stock if you expect a re-rating but want protection against a temporary digestion phase in AI spending.
• For more aggressive positioning, fade MRVL strength after any euphoric squeeze. Use tight stops, because the name can stay momentum-driven, but the risk/reward worsens materially once valuation becomes the main driver.